Perry Gordon

发表

Identification of novel potent bicyclic peptide deformylase inhibitors.

A. Kreusch, T. Shin, B. Bursulaya, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.

Jennifer L. Harris, A. Chatterjee, R. Epple, 2007, Bioorganic & medicinal chemistry letters.

Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.

J. Lao, A. Chatterjee, T. Tuntland, 2008, Bioorganic & medicinal chemistry letters.

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Ce

Chun Xing Li, S. Bender, G. Spraggon, 2016, Journal of medicinal chemistry.

A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer

P. Schultz, Jae Wook Lee, P. Mischel, 2019, Proceedings of the National Academy of Sciences.

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

Yingyao Zhou, G. Bonamy, K. Kuhen, 2011, Science.

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

Tao Jiang, Bo Liu, Glen Spraggon, 2017, ACS medicinal chemistry letters.

Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.

Jun Li, Glen Spraggon, Tove Tuntland, 2006, Bioorganic & medicinal chemistry letters.

Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.

Jun Li, Tove Tuntland, Jennifer L. Harris, 2006, Bioorganic & medicinal chemistry letters.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Jennifer L. Harris, A. Chatterjee, T. Hollenbeck, 2006, Bioorganic & Medicinal Chemistry Letters.

Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.

T. Junt, B. Nayak, C. Betschart, 2020, Bioorganic & medicinal chemistry letters.